Gastrointestinal Protocol - PANCREAS - S1513

S1513

Randomized Phase II Study of 2nd Line FOLFIRI versus Modified FOLFIRI with PARP Inhibitor ABT-888 (Veliparib) in Metastatic Pancreatic Cancer.